Tag Archive for: Macrophage

Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease

/in

RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events Enrolment is now open for the study, with initial data readout expected in 2026 Edinburgh and London, UK, 3 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a […]

Read more

Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper

/in

Resolution leadership team joined by world leading clinical hepatologist Elliot Tapper, MD, FAASLD, and EMERALD Chief Investigator Professor Jonathan Fallowfield Edinburgh and London, UK, 27 August 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces that it will host a virtual […]

Read more

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

/in

Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy (“RMT”) in inflammatory and fibrotic diseases,  today announces it has presented a poster at the Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution taking place on 8 – 11 December 2024 in […]

Read more

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease.

/in

– Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New preclinical data support superior anti-inflammatory and anti-fibrotic effect of RTX001, an engineered macrophage investigational therapy, compared to non-engineered macrophages. – RTX001 has recently entered into a Phase […]

Read more

Genesis Conference 2019: Meeting Biotech Rising Stars

/in

Chaired by Tara Raveendran of Shore Capital. Speakers from Asceneuron, Storm Therapeutics, Theragnostics & Macrophage. 

Read more